News and Announcements
LETTER TO EDITOR
Defining the optimal local treatment approach in stage III non-small cell lung cancer: Surgery versus concurrent chemoradiation after induction chemoimmunotherapy
Show Less
1 Department of Radiation Oncology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir,
Turkey
ARNM, 025400052 https://doi.org/10.36922/ARNM025400052
Received: 1 October 2025 | Accepted: 3 November 2025 | Published online: 17 November 2025
(This article belongs to the Special Issue Advances in Chemoradiotherapy in the Era of Precision Medicine)
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Conflict of interest
The author declares no conflict of interest.
References
- Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301-1311. doi:10.1200/JCO.21.01308. Erratum in: J Clin Oncol. 2022;40(17):1965. doi: 10.1200/JCO.22.01023
- Peters S, Tan DS, Gerber DE, et al. CheckMate 73L: Phase III study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab ± ipilimumab versus chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage III NSCLC. Immuno Oncol Technol. 2024;24:100808. doi: 10.1016/j.iotech.2024.100808
- Bradley JD, Sugawara S, Lee KH, et al. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2. ESMO Open. 2024;9:102986. doi: 10.1016/j.esmoop.2024.102986
- Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389(18):1672-1684. doi: 10.1056/NEJMoa2304875
- Cascone T, Spicer JD, Pulla MP. Perioperative nivolumab in resectable lung cancer. Reply. N Engl J Med. 2024;391(6): 573-574. doi: 10.1056/NEJMc2407267
- Forde PM, Spicer J, Provencio M, et al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2025;393(8):741-752. doi:10.1056/NEJMoa2502931